Proportion of Mutation of Epidermal Growth Factor Receptor (EGFR) Genes from Tissue Biopsy and Liquid Biopsy ctDNA in Lung Adenocarcinoma
DOI:
https://doi.org/10.36497/jri.v40i3.118Keywords:
ctDNA, EGFR Mutation, liquid biopsy, lung cancer, lung adenocarcinomaAbstract
Backgrounds: In recent years, circulating tumor DNA (ctDNA) has emerged as a specific and sensitive blood-based biomarker to detect EGFR mutations. This study aims to determine the diagnostic accuracy of ctDNA in detecting EGFR gene mutations in adenocarcinoma lung cancer. Methods: This study was a cross-sectional study with the subjects were adenocarcinoma lung cancer patients from histopathology or cytology examination and examined EGFR mutations from plasma tissue biopsy and ctDNA specimens from April 2018 to February 2019 in several hospitals in the Medan City. Results: There were 100 data have been collected, with male were 71 subjects and female were 29 subjects. Found 20 mutations, single mutations of tissue biopsy were 19 cases, del exon 19 were 12 cases, mutation in exon 21 (L858R) were 6 cases, mutation exon 21 (L861Q) was 1 case, del exon 19 and 21 (L861Q double mutations) was 1 case. From plasma ctDNA examination EGFR mutations were found 15 cases, del exon 19 were 12 cases and del exon 21 (L858R) were 3 cases. Conclusions: The highest proportion of EGFR mutations by sex were women from tissue biopsy or ctDNA, the most often frequency of EGFR mutations from tissue biopsy and ctDNA in single mutations and exons19. (J Respir Indo. 2020; 40(3): 150-5)Downloads
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30
Kemenkes RI, Pedoman Nasional Pelayanan Kanker 2014. Jakarta. Available at http://kanker.kemkes.go.id/guidelines_read.php?id=1&cancer=4
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883-92
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 64(1), 9–29 (2014).
Syahruddin E, Wulandari L, Muktiati N S, Rima A, Soerso N N, Ermayanti S, et al, 2018 Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patient. Journal: Lung cancer: Targets and Therapy 2018.9
Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32: 579-86.
Reck M, Hagiwara K, Han B, et al. ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. J Thorac Oncol 2016;11:1682-9.
Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget. 2010;1(7):497-514.
Wang S, Han X, Hu X, et al. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin Chim Acta 2014;430:63-70.
Huang Z, Wang Z, Bai H, et al. The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thorac Cancer 2012;3:334-40.
Oktaviyanti Ika Kustiyah. Mutasi Egfr Pada Pemeriksaan Sitologi Adenokarsinoma Paru. Berkala Kedokteran, Vol.11, No.2, Sep 2015: 213-219.
Sari, Lenny; Purwanto, Purwanto. Mutasi EGFR pada Non-Small Cell Lung Cancer di Rumah Sakit Kanker “Dharmais”. Indonesian Journal of Cancer, [S.l.], v. 10, n. 4, p. 131–136, sep. 2017. ISSN 2355-6811. Available at: http://www.indonesianjournalofcancer.or.id/e-journal/index.php/ijoc/article/view/489>.
Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32: 579-86.
Arriola E, et al. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS. Clin Transl Oncol. In press.
Marchetti A, Normanno N, Pinto C et al. Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica 102(3), 119–126 (2010).
Mia Elhidsi, Sita Laksmi Andarini, Achmad Hudoyo. Profil Mutasi Epidermal Growth Factor Receptor Pasien Adenokarsinoma Paru Usia Muda. J Respir Indo. 2016; 36: 244-8.
Downloads
Additional Files
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
